Your browser doesn't support javascript.
loading
Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study / 中国结合医学杂志
Chinese journal of integrative medicine ; (12): 168-174, 2019.
Article in English | WPRIM | ID: wpr-776614
ABSTRACT
OBJECTIVE@#To follow up the participants of the randomized clinical trial "Efficacy and Safety of Niaoduqing Particles () for Delaying Moderate-to-Severe Renal Dysfunction", and assess the long-term effects of Niaoduqing Particles on delaying the progression of renal dysfunction.@*METHODS@#Participants, who had previously been randomly assigned to receive Niaoduqing Particles or placebo for 24 weeks (146 cases in each group), were invited to follow-up and all were administered Niaoduqing Particles 5 g thrice daily and 10 g before bedtime for 24 weeks. The primary endpoints were changes in baseline serum creatinine (Scr) and estimated glomerular filtration rate (eGFR) after completion of the open-label treatment period.@*RESULTS@#After the double-blind period, the median (interquartile range) changes in Scr were 1.1 (-13.0-24.1) and 11.7 (-2.6-42.9) μmol/L for the Niaoduqing Particle and placebo groups, respectively (P=0.008), and the median changes in eGFRs were-0.2 (-4.3-2.7) and-2.21 (-5.7-0.8) mL•min•1.73 m, respectively (P=0.016). There were significant differences in the double-blind period changes in renal function between groups. After the open-label period, the median changes in Scr were 9.0 (-10.0-41.9) and 17.5 (-6.0-50.0) μmol/L for the Niaoduqing Particle and placebo groups according to baseline grouping, respectively (P=0.214), and the median changes in eGFRs were-2.3 (-6.4-1.9) and-3.7 (-7.5-1.1) mL•min•1.73 m, respectively (P=0.134). There were no statistical differences in the open-label period changes in renal function between groups. The eGFR reduction of participants who accepted Niaoduqing Particle treatment for 48 weeks was projected to 2.5 mL•min•1.73 m per year.@*CONCLUSION@#Niaoduqing Particles appear to have long-term efficacy for patients with moderate-to-severe renal dysfunction. Although there was no statistical difference, the early use of Niaoduqing Paticles seems to ameliorate the worsening of renal function. (Trial registration No. ChiCTR-TRC-12002448).
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Drugs, Chinese Herbal / Double-Blind Method / Follow-Up Studies / Outcome Assessment, Health Care / Disease Progression / Therapeutic Uses / Drug Therapy / Glomerular Filtration Rate / Kidney Diseases Type of study: Controlled clinical trial / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Chinese journal of integrative medicine Year: 2019 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Drugs, Chinese Herbal / Double-Blind Method / Follow-Up Studies / Outcome Assessment, Health Care / Disease Progression / Therapeutic Uses / Drug Therapy / Glomerular Filtration Rate / Kidney Diseases Type of study: Controlled clinical trial / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: Chinese journal of integrative medicine Year: 2019 Type: Article